Minimal Change Disease Clinical Trial
Official title:
Tacrolimus vs Prednisolone for the Treatment Minimal Change Disease
The purpose of this study is to compare the effectiveness of tacrolimus (prograf) versus prednisolone for the treatment of nephrotic syndrome secondary to minimal change disease.
Minimal change disease is a common cause of nephrotic syndrome in adults. Standard treatment is with high dose steroids which is often effective in controlling the nephrotic syndrome but has a high morbidity due to the side effects of the steroids. There is also a high relapse rate,therefore many patients require long term steroid therapy to control their disease which has significant morbidity and mortality. Some patients are or also become steroid resistant. There are studies showing the effectiveness of alkylating agents such as cyclophosphamide but the use of these drugs is limited by their toxicity, including increased rates of infection, cancers and infertility. Tacrolimus (prograf) is a T-cell specific calcineurin inhibitor that shares similar immunosuppressive actions with cyclosporine A.In other glomerular diseases such as focal segmental glomerulosclerosis and membranous glomerulonephritis, prograf has been shown to be a very effective treatment for proteinuria. This may be due to the immunomodulatory effects on the underlying disease, but there may also be a direct effect of tacrolimus (prograf) on the podocyte, stabilising the actin cytoskeleton and therefore decreasing protein leak.Therefore tacrolimus (prograf) is likely to be effective in reducing proteinuria in minimal change disease.It has also been shown to have a good side effect profile when used to allow the avoidance of steroids in transplantation.This study aims to prospectively study if tacrolimus (prograf) is effective as treatment for minimal change disease compared with standard therapy with steroids, and whether it has advantages in terms of side effect profile and prevention of relapse. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05588063 -
taVNS for FRNS in Children
|
N/A | |
| Recruiting |
NCT05583942 -
A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS)
|
N/A | |
| Completed |
NCT04369183 -
Rituximab for Refractory or Relapsed Focal Segmental Glomerulosclerosis or Minimal Change Disease
|
||
| Recruiting |
NCT02896270 -
Valproic Acid for Idiopathic Nephrotic Syndrome
|
Phase 2/Phase 3 | |
| Completed |
NCT04009668 -
Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
|
Phase 2 | |
| Terminated |
NCT05441826 -
Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)
|
Phase 2 | |
| Not yet recruiting |
NCT06405100 -
Efficacy and Safety of Tacrolimus in Combination With Ripertamab in the Initial Treatment of Patients With MCD
|
Phase 3 | |
| Recruiting |
NCT03929887 -
KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis
|
||
| Active, not recruiting |
NCT03210688 -
Active Vitamin D And Reduced Dose Prednisolone for Treatment in Minimal Change Nephropathy
|
Phase 4 | |
| Completed |
NCT02592798 -
Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)
|
Phase 2 | |
| Enrolling by invitation |
NCT04571658 -
NEPTUNE Match Study
|
||
| Completed |
NCT01084980 -
Therapeutic Effect of Tacrolimus in Combination With Low Dose Corticosteroid in Adult Patient With Minimal Change Nephritic Syndrome
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT06466135 -
Study of WAL0921 in Patients With Glomerular Kidney Diseases
|
Phase 2 | |
| Recruiting |
NCT03068572 -
Diagnostic Value of Linked Color Imaging for Minimal Change Esophagitis in Nonerosive Reflux Esophagitis and GERD
|
N/A | |
| Recruiting |
NCT05650619 -
Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
|
||
| Terminated |
NCT04235621 -
A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)
|
||
| Recruiting |
NCT03298698 -
Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome
|
Phase 3 | |
| Recruiting |
NCT05003986 -
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
|
Phase 2 | |
| Recruiting |
NCT05505500 -
Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.
|
||
| Not yet recruiting |
NCT06315504 -
Circulating Factors in Nephrotic Syndrome
|